REQUEST A DEMO
Total
USD $0.00
Search more companies

Cellid Co.,Ltd. (South Korea)

Main Activities: Biological Product (except Diagnostic) Manufacturing
Full name: Cellid Co.,Ltd. Profile Updated: June 19, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English Download a sample report

Cellid, Co., Ltd is a biotechnology company that specializes in anti-cancer immunotherapy. It develops cancer antigen gene pipelines using its CeliVax technology, targeting medical needs in various carcinomas. Cellid operates within the healthcare industry, focusing on cancer treatment.

Headquarters
5F, 142-Dong, College Of Pharmacy, Seoul Univ., 1, Gwanak-Ro, Gwanak-Gu
Seoul; Seoul;

Contact Details: Purchase the Cellid Co.,Ltd. report to view the information.

Website: http://www.cellid.co.kr

Basic Information
Total Employees:
Purchase the Cellid Co.,Ltd. report to view the information.
Outstanding Shares:
Purchase the Cellid Co.,Ltd. report to view the information.
Registered Capital:
Purchase the Cellid Co.,Ltd. report to view the information.
Financial Auditors:
Purchase the Cellid Co.,Ltd. report to view the information.
Incorporation Date:
December 11, 2006
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Ownership Details
Purchase this report to view the information.
19.4%
Purchase this report to view the information.
12.6%
Purchase this report to view the information.
2%
Subsidiaries
(주)셀리드
Company Performance
Financial values in the chart are available after Cellid Co.,Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
164.29%
Total operating revenue
141.36%
Operating Profit/Loss (EBIT)
6.04%
EBITDA
7.49%
Net Profit/Loss for the Period
12.77%
Total Assets
49.8%
Total Equity
43.8%
Operating Profit Margin (ROS)
230.26%
Net Profit Margin
254.48%
Return on Equity (ROE)
6.24%
Debt/Equity
10.99%
Quick Ratio
3.84%
Cash Ratio
-0.45%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?